» Articles » PMID: 33109237

Impact of Extracellular Matrix Stiffness on Genomic Heterogeneity in MYCN-amplified Neuroblastoma Cell Line

Overview
Publisher Biomed Central
Specialty Oncology
Date 2020 Oct 28
PMID 33109237
Citations 20
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Increased tissue stiffness is a common feature of malignant solid tumors, often associated with metastasis and poor patient outcomes. Vitronectin, as an extracellular matrix anchorage glycoprotein related to a stiff matrix, is present in a particularly increased quantity and specific distribution in high-risk neuroblastoma. Furthermore, as cells can sense and transform the proprieties of the extracellular matrix into chemical signals through mechanotransduction, genotypic changes related to stiffness are possible.

Methods: We applied high density SNPa and NGS techniques to in vivo and in vitro models (orthotropic xenograft vitronectin knock-out mice and 3D bioprinted hydrogels with different stiffness) using two representative neuroblastoma cell lines (the MYCN-amplified SK-N-BE(2) and the ALK-mutated SH-SY5Y), to discern how tumor genomics patterns and clonal heterogeneity of the two cell lines are affected.

Results: We describe a remarkable subclonal selection of genomic aberrations in SK-N-BE(2) cells grown in knock-out vitronectin xenograft mice that also emerged when cultured for long times in stiff hydrogels. In particular, we detected an enlarged subclonal cell population with chromosome 9 aberrations in both models. Similar abnormalities were found in human high-risk neuroblastoma with MYCN amplification. The genomics of the SH-SY5Y cell line remained stable when cultured in both models.

Conclusions: Focus on heterogeneous intratumor segmental chromosome aberrations and mutations, as a mirror image of tumor microenvironment, is a vital area of future research.

Citing Articles

Insights into the mechanisms, regulation, and therapeutic implications of extracellular matrix stiffness in cancer.

Zhang X, Al-Danakh A, Zhu X, Feng D, Yang L, Wu H Bioeng Transl Med. 2025; 10(1):e10698.

PMID: 39801760 PMC: 11711218. DOI: 10.1002/btm2.10698.


Real-time morphometric analysis of targeted therapy for neuroblastoma cells in monolayer and 3D hydrogels using digital holographic microscopy.

Granados-Aparici S, Vieco-Marti I, Lopez-Carrasco A, Navarro S, Noguera R iScience. 2024; 27(11):111231.

PMID: 39569369 PMC: 11576390. DOI: 10.1016/j.isci.2024.111231.


Characterization of Vitronectin Effect in 3D Ewing Sarcoma Models: A Digital Microscopic Analysis of Two Cell Lines.

Lopez-Carrasco A, Parra-Haro K, Vieco-Marti I, Granados-Aparici S, Diaz-Martin J, Salguero-Aranda C Cancers (Basel). 2024; 16(19).

PMID: 39409975 PMC: 11476106. DOI: 10.3390/cancers16193347.


Vitronectin Levels in the Plasma of Neuroblastoma Patients and Culture Media of 3D Models: A Prognostic Circulating Biomarker?.

Lopez-Carrasco A, Vieco-Marti I, Granados-Aparici S, Acevedo-Leon D, Estan-Capell N, Portugal R Int J Mol Sci. 2024; 25(16).

PMID: 39201421 PMC: 11354570. DOI: 10.3390/ijms25168733.


Applications of 3D Bioprinting Technology to Brain Cells and Brain Tumor Models: Special Emphasis to Glioblastoma.

Ozbek I, Saybasili H, Ulgen K ACS Biomater Sci Eng. 2024; 10(5):2616-2635.

PMID: 38664996 PMC: 11094688. DOI: 10.1021/acsbiomaterials.3c01569.


References
1.
Janoueix-Lerosey I, Schleiermacher G, Michels E, Mosseri V, Ribeiro A, Lequin D . Overall genomic pattern is a predictor of outcome in neuroblastoma. J Clin Oncol. 2009; 27(7):1026-33. DOI: 10.1200/JCO.2008.16.0630. View

2.
Yan B, Kuick C, Lim M, Venkataraman K, Tennakoon C, Loh E . Platform comparison for evaluation of ALK protein immunohistochemical expression, genomic copy number and hotspot mutation status in neuroblastomas. PLoS One. 2014; 9(9):e106575. PMC: 4154751. DOI: 10.1371/journal.pone.0106575. View

3.
Lasorsa V, Formicola D, Pignataro P, Cimmino F, Calabrese F, Mora J . Exome and deep sequencing of clinically aggressive neuroblastoma reveal somatic mutations that affect key pathways involved in cancer progression. Oncotarget. 2016; 7(16):21840-52. PMC: 5008327. DOI: 10.18632/oncotarget.8187. View

4.
Tadeo I, Gamero-Sandemetrio E, Berbegall A, Gironella M, Ritort F, Canete A . Lymph microvascularization as a prognostic indicator in neuroblastoma. Oncotarget. 2018; 9(40):26157-26170. PMC: 5995242. DOI: 10.18632/oncotarget.25457. View

5.
Zhong J, Yang Y, Liao L, Zhang C . Matrix stiffness-regulated cellular functions under different dimensionalities. Biomater Sci. 2020; 8(10):2734-2755. DOI: 10.1039/c9bm01809c. View